Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion type Assertion NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_head.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion description "[Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of acquired imatinib resistance in patients with chronic myeloid leukemia (CML).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_provenance.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion evidence source_evidence_literature NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_provenance.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion SIO_000772 17496200 NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_provenance.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion wasDerivedFrom befree-2016 NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_provenance.
- NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_assertion wasGeneratedBy ECO_0000203 NP609455.RAcFpm5JxEw05Wsr-JIgG_Ols5xxI2D91kK4Zmz6AhF9o130_provenance.